New study peeks inside pancreatic tumors to find better drug targets
NCT ID NCT04005690
First seen Mar 05, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers will give one of several drugs (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, or tremelimumab) for a short time before surgery or biopsy. By comparing tumor samples before and after treatment, they hope to learn which drugs change the tumor's biology. This information will help design future trials to find better treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.